Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 16/20 | 0.45 |
| ▸ | CNR2 | P34972 | 13/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18970401 | 0.86 | S1PR1 (0.45) | S1PR1CNR1CNR2GLA | |
| SCHEMBL13159690 | 0.84 | S1PR1 (0.47) | S1PR1CNR1CNR2GLA | |
| SCHEMBL12302870 | 0.84 | CNR1 (0.44) | S1PR1CNR1CNR2GLA | |
| SCHEMBL25853587 | 0.84 | S1PR1 (0.47) | S1PR1CNR1CNR2GLA | |
| SCHEMBL12488294 | 0.83 | S1PR1 (0.45) | S1PR1CNR1CNR2GLA | |
| SCHEMBL22432045 | 0.83 | CNR1 (0.46) | S1PR1CNR1CNR2GLA | |
| SCHEMBL5545605 | 0.82 | CNR1 (0.43) | S1PR1CNR1CNR2GLA | |
| SCHEMBL20878279 | 0.82 | CNR1 (0.44) | S1PR1CNR1CNR2GLA | |
| SCHEMBL18896215 | 0.82 | S1PR1 (0.45) | S1PR1CNR1CNR2GLA | |
| SCHEMBL19223931 | 0.82 | CNR1 (0.45) | S1PR1CNR1CNR2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-20210395228-A1 | PESTICIDALLY ACTIVE BENZENE- AND AZINE-AMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-12-23 | — | — | US | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| EP-3686197-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-10710995-B2 | Inhibitors of β-hydroxylase for treatment of cancer | RHODE ISLAND HOSPITAL (US) | 2020-07-14 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10647699-B2 | Substituted 2-oxyimidazolylcarboxamides as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-05-12 | — | — | US | disclosed |
| US-20200115356-A1 | Modulation of Bacterial Quorum Sensing With Synthetic Ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-04-16 | — | — | US | disclosed |
| US-20080096134-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080081289-A1 | RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080081292-A1 | RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080076062-A1 | RESIST COMPOSITION AND PATTERN-FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080050675-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20070224539-A1 | Resist composition and pattern forming method using the same | FUJIFILM CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070218406-A1 | Acid generator; exposure to actinic radiation | FUJIFILM CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070218407-A1 | Positive resist composition and pattern forming method using the same | FUJIFILM CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070072121-A1 | Positive resist composition and pattern forming method using the same | FUJI PHOTO FILM CO., LTD. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | HDAC4 1452/4885HDAC2 553/4885HDAC8 1379/4885 |
| US-20200115356-A1 | Modulation of Bacterial Quorum Sensing With Synthetic Ligands | AHCYL1, EBPL, AIP | HDAC4 3532/4885HDAC2 4503/4885HDAC8 3762/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HDAC4 701/4885HDAC2 576/4885HDAC8 1335/4885 |
| US-10647699-B2 | Substituted 2-oxyimidazolylcarboxamides as pesticides | DDT, PRXL2A, TSNAX | HDAC4 1797/4885HDAC2 590/4885HDAC8 2044/4885 |
| US-20210395228-A1 | PESTICIDALLY ACTIVE BENZENE- AND AZINE-AMIDE COMPOUNDS | DDT, ACHE, NAT1 | HDAC4 1493/4885HDAC2 1044/4885HDAC8 660/4885 |
| US-10710995-B2 | Inhibitors of β-hydroxylase for treatment of cancer | ASPH, CYP46A1, AHR | HDAC4 473/4885HDAC2 357/4885HDAC8 577/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | HDAC4 1590/4885HDAC2 1269/4885HDAC8 2336/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | HDAC4 1067/4885HDAC2 934/4885HDAC8 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.